Funck, Kristian Løkke
Bjerg, Lasse
Isaksen, Anders Aasted
Sandbæk, Annelli
Grove, Erik Lerkevang
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 28 October 2022
Accepted: 1 December 2022
First Online: 10 December 2022
Declarations
:
: Not applicable.
: The authors approve to be accountable for all aspects of the work and will work to resolve or investigate any questions related to the accuracy or integrity of any part of the work. ELG is the guarantor of the work. The authors consent for this publication. The main study results have been presented by KLF at the 58th Annual Meeting of the European Association for the Study of Diabetes, Stockholm.
: KLF and ELG has received an unrestricted research grant for the present study from Boehringer Ingelheim. KLF has no additional conflicts to declare. LBH and AS report no personal conflicts of interest. ELG has received speaker honoraria or consultancy fees from Alexion Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol–Myers Squibb, Pfizer, MSD, MundiPharma, and Lundbeck Pharma. He is an investigator in studies sponsored by AstraZeneca or Bayer and has received unrestricted research grants from Boehringer Ingelheim.